跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 16 条关于
“maytansinoid”
全部
16
临床试验
1
药物
5
机构
0
资讯
10
去年
Cybrexa's Novel Peptide-Drug Conjugates Show Promising Tumor-Selective Activity in Preclinical Studies
去年
CHMP Recommends Mirvetuximab Soravtansine (ELAHERE®) for Platinum-Resistant Ovarian Cancer
去年
AbbVie's Elahere Receives European Commission Approval for Platinum-Resistant Ovarian Cancer
去年
European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer
5年前
STRO-001 Shows Promise in Relapsed/Refractory B-Cell NHL
去年
ELAHERE Shows 32% Reduction in Death Risk for Platinum-Resistant Ovarian Cancer in Final MIRASOL Trial Analysis
7个月前
OEB 6 Emerges as New Manufacturing Standard for Ultra-Potent Oncology Drugs and ADCs
9个月前
HER2-Negative Breast Cancer Pipeline Expands with 75+ Therapies from 70+ Companies
去年
Federal Circuit Ruling on ImmunoGen's Dosing Patent Highlights Challenges in Pharmaceutical Patent Strategy
去年
ADCs Transform NSCLC Treatment Landscape with Multiple FDA Approvals and Expanding Clinical Applications